Syngene International has announced a strategic collaboration with John Hopkins University to advance early-stage drug discovery programmes.  The collaboration will incorporate Syngene’s SynVent, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development.   Syngene also intends to use its Connector model, designed to bridge […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!